Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:5:121-7.
doi: 10.2147/IDR.S25874. Epub 2012 Aug 8.

Current management of parainfluenza pneumonitis in immunocompromised patients: a review

Affiliations

Current management of parainfluenza pneumonitis in immunocompromised patients: a review

Ann R Falsey. Infect Drug Resist. 2012.

Abstract

Parainfluenza viruses (PIV) are common respiratory viruses that belong to the Paramyxoviridae family. PIV infection can lead to a wide variety of clinical syndromes ranging from mild upper respiratory illness to severe pneumonia. Severe disease can be seen in elderly or chronically ill persons and may be fatal in persons with compromised immune systems, particularly children with severe combined immunodeficiency disease syndrome and hematopathic stem cell transplant recipients. At present, there are no licensed antiviral agents for the treatment of PIV infection. Aerosolized or systemic ribavirin in combination with intravenous gamma globulin has been reported in small, uncontrolled series and case reports of immunocompromised patients. A number of agents show antiviral activity in vitro and in animals, but none are currently approved for human use.

Keywords: antiviral agents; immunocompromised host; parainfluenza virus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of the parainfluenza virion. © 2005, American Society for Clinical Investigation. Reproduced with permission from Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest. 2005;115(7):1688–1698. Abbreviation: HN, Hemagglutinin-neuraminidase protein.
Figure 2
Figure 2
Schematic illustration of the parainfluenza life cycle. © 2005, American Society for Clinical Investigation. Reproduced with permission from Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest. 2005;115(7):1688–1698. Abbreviation: RER, rough endoplasmic reticulum; HPIV, human parainfluenza virus; L, large RNA polymerase protein; M, matrix protein; NP, nucleocapsid protein; P, phosphoprotein.
Figure 3
Figure 3
Percent mortality broken down by treatment group and presence or absence of co-pathogens. Figure © 2001, American Society for Blood and Marrow Transplantation. Adapted with permission from Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7 Suppl:11S–15S. Abbreviation: IVIG, intravenous gammaglobulin.

Similar articles

Cited by

References

    1. Henrickson KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16(2):242–264. - PMC - PubMed
    1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–1928. - PubMed
    1. Rihkanen H, Ronkko E, Nieminen T, et al. Respiratory viruses in laryngeal croup of young children. J Pediatr. 2008;152(5):661–665. - PMC - PubMed
    1. Stankova J, Carret AS, Moore D, et al. Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency. Pediatr Transplant. 2007;11(2):209–213. - PubMed
    1. Moss RB, Steigbigel RT, Sanders RL, Fang F. Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patients. Adv Virol. 2011;2011:910930. Epub July 7, 2011. - PMC - PubMed

LinkOut - more resources